针对CD19CAR-T治疗失败或CD19阴性复发的患者群体，LY007提供了新的治疗选择。其CAR-T细胞在 患者体内扩增峰值达CD3+T细胞的46%至80%。 LY007采用独特的OX40共刺激信号结构设计，显著增强T细胞扩增能力与抗肿瘤活性。I期临床试验数 据显示，在12例复发╱难治性CD20阳性B细胞型非霍奇金淋巴瘤患者中，92%患者实现肿瘤缩小或消 失，最佳完全缓解率(BCRR)达75%。1例曾接受CD19CAR-T治疗失败的患者亦获得完全缓解，且未发 生严重细胞因数风暴或神经毒性。 2.差异化适应症布局 中国生物科技服务(08037)发布公告，继去年在美展示临床试验结果后，公司间接非全资附属公司上海 隆耀生物科技有限公司(上海隆耀)即将于2025年6月17日至2025年6月21日于瑞士卢加诺举行的第18届国 际恶性淋巴瘤会议(ICML)及于2025年6月12日至2025年6月15日于意大利米兰举行的第30届欧洲血液学 年会(EHA)上以海报展示形式展示有关LY007细胞注射液的I期研究临床试验结果。 LY007的临床成果亮点为填补CD20CAR-T治疗空白。 1.高效性与安全性并重 上海隆耀计划于国 ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 年報 2024 精準治療 Precision Treatment 精準檢測 Precision Diagnosis 未來生物科技平臺 Future Biotech Platform 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有較高投資風險。 有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波動風險， 同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was HKD 70,509,000, a decrease of 66.7% compared to HKD 211,985,000 in 2023[3] - The gross loss for the year was HKD 4,940,000, compared to a gross profit of HKD 34,324,000 in the previous year[3] - Operating loss increased to HKD 143,048,000 from HKD 127,674,000 year-over-year[3] - The total comprehensive loss for the year was HKD 268,982,000, compared to HKD 174,253,000 in 2023, representing a 54.3% increase[4] - Basic and diluted loss per share was HKD 0.205, compared to HKD 0.099 in the previous year[4] - The group reported a loss of approximately HKD 251,854,000 for the year ended December 31, 2024[14] - The company reported a total loss before tax of HKD 252,797,000 for the year ended December 31, 2024, compared to a loss of HKD 142,025,000 in 2023[27][29] - The group recorded a net loss attributable to shareholders of approximately HKD 198,146,000 in 2024, an increase from HKD 95,447,000 in 2023[69] Assets and Liabilities - Total assets decreased to HKD 529,955,000 from HKD 662,362,000, a decline of 20.0%[5] - Total equity decreased to HKD 242,388,000 from HKD 490,726,000, a drop of 50.6%[6] - The total liabilities of the company as of December 31, 2024, were HKD 287,567,000, compared to HKD 171,636,000 in 2023[27][29] - As of December 31, 2024, the group's current liabilities exceeded its current assets by approximately HKD 129,519,000[14] - The total current assets decreased from HKD 39,636,000 in 2023 to HKD 25,416,000 in 2024, a decline of about 36%[35] Revenue Breakdown - Revenue from medical laboratory testing and health check services was HKD 39,158,000, down from HKD 192,910,000, indicating a decrease of about 79.7%[23] - Insurance brokerage services revenue increased to HKD 30,600,000 from HKD 18,163,000, reflecting a growth of approximately 68.4%[23] - The segment loss for the medical and healthcare services division was HKD 100,150,000 for the year ended December 31, 2024[27] - The overall demand for medical laboratory testing and health check services was weaker than expected in fiscal year 2024, attributed to local consumption recovery challenges post-pandemic[52] Financing and Capital Structure - The company has issued convertible bonds amounting to HKD 41,635,000, which were not present in the previous year[6] - The company plans to redeem USD 4,000,000 (approximately HKD 31,400,000) of the convertible bonds on December 17, 2024[40] - A new convertible bond issuance of USD 6,000,000 (approximately HKD 47,100,000) occurred on December 27, 2024, with an initial conversion price of HKD 1.20 per share[41] - The company has secured loans from controlling shareholders amounting to approximately HKD 24,772,000 as of December 31, 2024, with a fixed interest rate of 10%[90] - The group is actively seeking alternative financing and loans to meet its current financial obligations and future operational and capital expenditures, having secured approximately HKD 6,000,000 in additional loans as of the financial statement approval date[16] Impairment and Losses - The company reported a net impairment loss on property, plant, and equipment of HKD 52,713,000, compared to HKD 16,186,000 in 2023[3] - The impairment loss recognized for construction projects due to damage was approximately HKD 52,713,000[24] - The group recognized impairment losses of approximately HKD 13,374,000 and HKD 2,584,000 for intangible assets and right-of-use assets, respectively, related to the acquisition of DVF[67] Strategic Initiatives and Future Plans - The group has entered into a strategic cooperation framework agreement with Shenzhen Huada Gene Technology Co., Ltd., and an investment intention letter with investors for a potential investment of RMB 20 million to 30 million in Pengbo (Hainan)[16] - The company aims to be the first provider of boron neutron capture therapy services in Greater China, targeting inoperable, locally advanced, or locally recurrent head and neck cancer patients[85] - The company has launched a series of early health screening tests, including diabetes and HPV, to capitalize on the increased public awareness of health due to the pandemic[82] - The company continues to develop its anti-tumor cell therapy products, with clinical trials for its CAR-T drug progressing as planned[83] Governance and Compliance - The board of directors includes three executive directors and three independent non-executive directors[129] - The company has maintained compliance with the GEM listing rules regarding public float requirements[128] - The independent auditor's report indicated a significant uncertainty regarding the group's ability to continue as a going concern[112]

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 32,449,000, a decrease of 82.2% compared to HKD 182,357,000 in the same period of 2023[2]. - Gross loss for the period was HKD 3,107,000, compared to a gross profit of HKD 61,326,000 in the previous year[2]. - Operating loss increased to HKD 124,588,000 from HKD 34,067,000 year-on-year, reflecting a significant decline in performance[2]. - Total comprehensive loss for the period was HKD 132,973,000, compared to HKD 44,983,000 in the same period last year[4]. - The company reported a basic and diluted loss per share of HKD 0.083, compared to HKD 0.032 in the previous year[4]. - The group recorded a pre-tax loss of HKD 126,258 thousand for the period, compared to a pre-tax loss of HKD 24,677 thousand in the same period last year[15]. - The total loss for the period was HKD 125,731 thousand, compared to a loss of HKD 27,721 thousand in the previous year, indicating a significant increase in losses[16]. - For the six months ended June 30, 2024, the company reported a loss attributable to owners of approximately HKD 79,917,000, compared to a loss of HKD 30,484,000 for the same period in 2023[36]. Assets and Liabilities - Total assets as of June 30, 2024, were HKD 630,553,000, down from HKD 662,362,000 at the end of 2023[6]. - Non-current assets increased to HKD 238,275,000 from HKD 100,535,000, indicating substantial investment in property, plant, and equipment[5]. - Current assets decreased to HKD 473,486,000 from HKD 401,196,000, with a notable reduction in cash and bank balances[5]. - Equity attributable to owners of the company decreased to HKD 390,217,000 from HKD 462,754,000, reflecting a decline in shareholder value[6]. - Total liabilities increased to HKD 249,229,000 as of June 30, 2024, compared to HKD 171,636,000 as of December 31, 2023[18]. Cash Flow - For the six months ended June 30, 2024, the net cash used in operating activities was HKD (95,539) thousand, compared to HKD 310,855 thousand for the same period in 2023, indicating a significant decrease in cash flow from operations[10]. - The total cash and cash equivalents at the end of the period decreased to HKD 33,241 thousand from HKD 245,396 thousand a year earlier, indicating a decline in liquidity[10]. - The company reported a net decrease in cash and cash equivalents of HKD (38,449) thousand for the period, compared to an increase of HKD 155,283 thousand in the same period last year, highlighting a shift in cash management[10]. Revenue Breakdown - Revenue from medical laboratory testing and health check services was HKD 19,729 thousand, down from HKD 170,525 thousand year-on-year, indicating a decrease of about 88.4%[15]. - The insurance brokerage services generated revenue of HKD 12,255 thousand, compared to HKD 11,467 thousand in the previous year, reflecting an increase of approximately 6.9%[13]. - The logistics services segment reported revenue of HKD 28 thousand, significantly up from HKD 9 thousand in the prior year, marking a growth of approximately 211.1%[13]. - The decline in revenue was primarily due to the cessation of mandatory COVID-19 nucleic acid testing services by the Hong Kong government, which significantly impacted income[61]. Strategic Focus - The company is focusing on precision treatment and diagnosis as part of its future biotech platform strategy[1]. - The company continues to focus on providing medical laboratory testing services and health check services in Hong Kong, as well as cancer immunotherapy and health management services in China[12]. - The company is engaged in the sale and distribution of health-related and pharmaceutical products in both China and Hong Kong, indicating ongoing market expansion efforts[12]. Investments and Capital Expenditures - Capital expenditures for the six months ended June 30, 2024, were HKD 161,813,000, a significant increase from HKD 16,730,000 in the same period of 2023[19]. - The company completed a capital injection agreement amounting to RMB 49,960,000 into Shanghai Longyao, acquiring a 5.57% equity interest[46]. - The company has capital commitments of HKD 91,938,000 for boron neutron capture therapy equipment and center construction, down from HKD 208,295,000 as of December 31, 2023[54]. Shareholder Information - The company did not recommend any dividend for the six months ended June 30, 2024, consistent with the previous period[36]. - As of June 30, 2024, the total issued shares were 963,231,150, with Liu Xiaolin holding approximately 54.97% of the shares[86]. - Major shareholders include entities holding significant stakes, such as 529,500,546 shares (54.97%) and 187,903,805 shares (19.51%) respectively[90]. Corporate Governance - The board emphasizes the importance of corporate governance for the company's success and has implemented measures to ensure compliance with laws and regulations[107]. - The audit committee, consisting of three independent non-executive directors, oversees the financial reporting process and internal controls[108]. - The company has adopted a code of conduct for directors regarding securities trading, confirming compliance during the interim period of 2024[106].

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 32,449,000, a decrease of 82.2% compared to HKD 182,357,000 for the same period in 2023[2]. - Gross loss for the period was HKD 3,107,000, compared to a gross profit of HKD 61,326,000 in the previous year[2]. - Operating loss increased to HKD 124,588,000 from HKD 34,067,000 year-on-year[2]. - Loss for the period was HKD 125,731,000, significantly higher than the loss of HKD 27,721,000 in the same period last year[3]. - The company reported a total comprehensive loss of HKD 132,973,000 for the period, compared to HKD 44,983,000 in the same period last year[3]. - The group reported a gross loss of approximately HKD 3,107,000, a decrease of about HKD 64,433,000 compared to a gross profit of HKD 61,326,000 in the previous period[71]. - The company recorded a net loss attributable to shareholders of approximately HKD 79,917,000, an increase from HKD 30,484,000 in the previous period, driven by reduced demand for COVID-19 testing and increased competition in the medical laboratory services market[75]. Assets and Liabilities - Total assets as of June 30, 2024, were HKD 630,553,000, down from HKD 662,362,000 as of December 31, 2023[4]. - Total liabilities as of June 30, 2024, were HKD 249,229,000, compared to HKD 171,636,000 as of December 31, 2023, indicating an increase in liabilities[20]. - Current assets decreased to HKD 157,067,000 from HKD 261,166,000 as of December 31, 2023[4]. - The company’s total equity as of June 30, 2024, was HKD 656,862,000, down from HKD 826,520,000 at the beginning of the year[9]. - The company’s total assets as of June 30, 2024, were HKD 490,692,000[9]. - The company’s current liabilities have increased, leading to a current ratio of 0.74 as of June 30, 2024, down from 1.64 as of December 31, 2023[86]. Cash Flow - For the six months ended June 30, 2024, the company reported a net cash outflow from operating activities of HKD (95,539) thousand, compared to a net inflow of HKD 310,855 thousand in the same period of 2023[10]. - The net cash used in investing activities was HKD (61,468) thousand, an improvement from HKD (144,737) thousand in the previous year[10]. - Financing activities generated a net cash inflow of HKD 118,558 thousand, contrasting with a net cash outflow of HKD (10,835) thousand in the prior period[10]. - As of June 30, 2024, the company's cash and cash equivalents decreased to HKD 33,241 thousand from HKD 245,396 thousand at the end of June 2023[10]. Revenue Breakdown - Revenue from medical laboratory testing and health check services was HKD 19,729 thousand, down 88.4% from HKD 170,525 thousand in the previous year[14]. - The insurance brokerage services generated revenue of HKD 12,255 thousand, an increase of 6.9% from HKD 11,467 thousand in the prior year[14]. - The logistics services segment reported revenue of HKD 28 thousand, significantly up from HKD 9 thousand in the previous year[14]. - The decline in revenue was primarily due to the cessation of mandatory COVID-19 testing services by the end of February 2023, leading to an adjusted revenue decrease of 16.47% in the medical laboratory testing segment[64]. Business Segments - The group operates five business segments, including medical and health-related services, immunotherapy, boron neutron capture therapy, pharmaceutical products, and insurance brokerage[15]. - The group continues to face challenges in demand for diagnostic and health check services, attributed to weak market conditions and intensified competition among peers[65]. Investments and Capital Expenditures - Capital expenditures for the six months ended June 30, 2024, were HKD 161,813,000, significantly higher than the previous period[21]. - The company entered into a capital injection agreement on December 8, 2023, committing RMB 49,960,000 to Shanghai Longyao, acquiring a 5.57% equity interest[44]. - The company has made a first payment of approximately HKD 51,765,000 for boron neutron capture therapy equipment, with a remaining contract price of approximately HKD 14,565,000 expected to be paid in 2024[54]. Shareholder Information - The company did not recommend any dividend for the six months ended June 30, 2024, consistent with the previous year[30]. - The total number of issued shares of the company is 963,231,150, with a par value of HKD 0.10 per share[104]. - Genius Earn holds 529,500,546 shares, representing approximately 54.97% of the company's total shares[103]. Corporate Governance - The board emphasizes the importance of corporate governance and has implemented measures to ensure compliance with laws and regulations, maintaining high standards of integrity and transparency[125]. - An audit committee has been established to review and supervise the group's financial reporting procedures and internal controls, consisting of three independent non-executive directors[127]. Future Plans and Developments - The company aims to become the first provider in Greater China to offer boron neutron capture therapy for patients with inoperable head and neck cancers, enhancing advanced radiation treatment services[81]. - The company plans to expand its medical laboratory testing and health check services to provide public health screening in Hong Kong, responding to increased demand post-pandemic[80]. - The company has initiated preparations for the Phase II clinical trial of LY007, with full registration of 13 patients expected to be completed by October 2024[66].

智通财经APP讯，中国生物科技服务(08037)公布，港深创新及科技园有限公司与大约60个合作伙伴机构(包括该公司)签署谅解备忘录后，已于2024年4月18日举行港深创科园合作伙伴启动礼。根据公司与港深创科园公司所订立的谅解备忘录，有关各方已经协定合作开发位于河套深港科技创新合作区落马洲河套地区的港深创新及科技园。 根据谅解备忘录，该公司将会透过以下方式支援创科园内的创新及科技(创科)创业公司取得市场准入：(1) 引进公司约五家附属公司及伙伴公司落地创科园，并协助其拓展至中国及海外市场;(2) 在创科园设立分子诊断实验室、嵌合抗原受体T细胞(CAR-T)开发中心及硼中子俘获治疗中心，员工人数约为200人，并以优惠价格为创科园的社区公司及公众人士提供合约研究机构服务，包括CAR-T细胞制造、研究和开发细胞治疗、硼中子俘获治疗及研发，以及其他专业服务;(3) 考虑在创科园内设立其他研发中心。 另一方面，港深创科园公司将会透过以下方式接纳该公司进驻以到创科园以建立驻点及扩大公司的网络，从而支持公司的业务拓展：(1) 透过不同的企业家计划，便利公司的附属公司及伙伴公司进驻创科园，并提供办公室租赁及必要的业务营运支援; ...

Environmental Impact - The total greenhouse gas emissions related to the company's operations for Scope 1 and 2 were estimated at 787 tons of CO2 equivalent in 2023, with a significant reduction attributed to changes in the operations of Huasheng Diagnostic Center Limited[37] - The company continues to implement sustainable practices in its R&D, medical testing, and precision diagnosis businesses to minimize its environmental footprint[29] - The company has established multiple environmental policies to ensure compliance with applicable laws and regulations in China and Hong Kong[30] - The company has implemented a waste management policy to ensure compliance with local regulations regarding medical waste disposal[39] - Medical waste is separated from other waste to prevent contamination, and licensed contractors are employed for safe collection and disposal[40] - The company has successfully reduced non-hazardous waste significantly following the completion of a business unit's construction activities in 2023[42] - The company has adopted energy-saving policies and practices in the office, including adjusting air conditioning to 25.5 degrees Celsius[58] - The company has not recorded any violations of environmental laws and regulations during the reporting period[62] - The company plans to reassess its environmental key performance indicators to track performance more consistently due to fluctuations in business scale and environmental performance[68] - Total energy consumption decreased significantly to 7,204 GJ in 2023 from 103,633 GJ in 2022, representing a reduction of approximately 93%[69] - Greenhouse gas emissions totalled 843 tonnes of CO2 equivalent in 2023, down from 11,273 tonnes in 2022, indicating a reduction of about 92.5%[69] - The total amount of hazardous waste generated increased to 128.4 tonnes in 2023 from 105.7 tonnes in 2022, reflecting a rise of approximately 21.5%[69] - The total water consumption rose to 11,556 cubic meters in 2023, compared to 7,374 cubic meters in 2022, marking an increase of about 56%[69] - The density of greenhouse gas emissions per 1,000 HKD revenue improved to 0.00398 tonnes CO2 equivalent in 2023 from 0.00609 tonnes in 2022, showing an enhancement of approximately 34%[69] - The total amount of non-hazardous waste generated was 423.3 tonnes in 2023, a significant decrease from 10,137.2 tonnes in 2022, indicating a reduction of approximately 95.8%[69] - The company has set a five-year environmental goal to promote waste reduction and will review progress annually, particularly in its core operations in China and Hong Kong[93] Corporate Governance - The company encourages shareholders to participate in annual general meetings and supports principles of corporate governance[13] - The company has a shareholder communication policy that promotes two-way communication with shareholders[12] - The company has adopted corporate governance measures to maintain high standards of governance and ensure compliance with legal and regulatory requirements[151] - The board of directors consists of three executive directors, one non-executive director, and three independent non-executive directors as of December 31, 2023[152] Risk Management - The company has identified and analyzed risks to achieve its group objectives through a dynamic interactive process[6] - The company has a framework for regularly reviewing its ESG performance, including stakeholder engagement and feedback collection[24] - The group has implemented various risk management assessment tools, including FMECA, FTA, and HAZOP, to minimize quality risks and develop continuous improvement strategies[192] - The group has identified key risks including intense competition in the industry, which may adversely affect demand for its products and services[179] - The group will closely monitor changes in the macroeconomic environment and adjust its product diversification plans and marketing strategies accordingly[182] Employee Management - Employee turnover rate for full-time staff was reported at 28% in 2023, while part-time staff had a significantly higher turnover rate of 60%[88] - The company provides competitive compensation and benefits plans to attract and retain elite talent for long-term structural growth[96] - Employee safety is a top priority, with a commitment to maintaining high occupational safety and health standards[97] - 53% of male employees and 36% of female employees received training, with an average training duration of 5.1 hours for males and 6.3 hours for females[106] - The company conducts safety inspections of laboratory units and surrounding areas every two years to ensure compliance with safety standards[100] - The company has not reported any significant non-compliance with safety standards or regulations regarding occupational hazards in 2023[103] - The company has implemented an eight-hour workday and a five-day workweek system to ensure fair labor practices[109] - The management regularly reviews employee compensation based on market trends, inflation, and performance metrics[97] - The group has implemented a comprehensive human resources policy that includes equal opportunity and anti-discrimination measures[127] - The group has a commitment to not tolerate forced labor or child labor, ensuring compliance with relevant labor laws[129] - The group’s employee benefits include mandatory provident fund contributions, insurance, and training programs[138] Financial Performance - The audit fees payable to the auditor for audit services amounted to HKD 1,200,000 for the year 2023, consistent with the previous year[11] - The total employee cost for the fiscal year 2023 was approximately HKD 92,607,000, a decrease of 44.4% compared to HKD 166,735,000 in 2022[138] - The group employed a total of 162 full-time employees as of December 31, 2023, down from 260 in 2022, indicating a reduction of 37.7%[138] - The overall employee turnover rate for the group during the reporting period was 29%[131] - The group made contributions of approximately HKD 2,996,000 to retirement benefit plans in 2023, compared to HKD 3,271,000 in 2022, reflecting a decrease of 8.4%[139] - The group maintains a strong liquidity position to seize growth opportunities, adhering to prudent cash management policies[135] - The group does not face significant foreign exchange risks and has not employed any financial instruments for hedging purposes[136] - The group’s management will continue to monitor and manage risks associated with interest rate and exchange rate fluctuations[136] Investments - The company holds approximately 3.01% equity interest in Pillar, valued at HKD 52,204,000 (equivalent to USD 6,684,000) as of December 31, 2023, down from HKD 69,270,000 (equivalent to USD 8,881,000) in the previous year, representing 7.88% of the company's total assets[153] - The fair value loss on the investment in Pillar for the year 2023 was approximately HKD 17,066,000, compared to a fair value gain of HKD 1,330,000 in 2022[153] - Pillar recorded an unaudited consolidated loss of approximately USD 22,100,000 for the year ending December 31, 2023[153] - The group holds approximately 1.13% equity interest in Kubo, equivalent to 5,970,160 shares, with a fair value of approximately HKD 4,716,000 as of December 31, 2023, down from HKD 13,672,000 a year earlier[154] - Kubo reported an unaudited consolidated loss of approximately USD 14.7 million for the six months ending June 30, 2023[154] - The fair value loss on the investment in Kubo for the year was approximately HKD 8,956,000, compared to HKD 39,358,000 in the previous year[154] - The group did not receive any dividend income from Kubo during the two years[154] - The group aims to strategically allocate resources towards precision diagnostics and enter the precision treatment industry through its investment in Kubo[154] Community Engagement - The group donated a total of HKD 105,000 to various charitable activities in 2023[176] - The group has established a whistleblowing channel to report misconduct and ensure transparency and accountability[174] - In the fiscal year 2023, the group made charitable donations of approximately HKD 105,000, compared to zero in the fiscal year 2022[187] - The group encourages employee participation in community service and has committed resources to support future community engagement efforts[200] Compliance and Ethics - The group strictly adheres to all relevant anti-corruption laws and has established policies to guide employees on measures against bribery and corruption[197] - There were no concluded corruption litigation cases against the company or its employees during the reporting period[199]

Financial Performance - The company reported a gross profit of approximately HKD 34,324,000 for the fiscal year 2023, a decrease of about HKD 1,066,633,000 compared to HKD 1,100,957,000 in fiscal year 2022, resulting in a gross margin of 16.19%, down 43.27 percentage points from 59.46% in the previous year[28]. - The net loss attributable to the company's owners for fiscal year 2023 was approximately HKD 95,447,000, compared to a net profit of HKD 258,087,000 in fiscal year 2022, primarily due to a decline in demand for COVID-19 testing services and rapid antigen test kits following the easing of quarantine regulations[32]. - The company reported total revenue for the year ended December 31, 2023, was HKD 211,985,000, a decrease of 88.6% from HKD 1,851,601,000 in 2022[115]. - The net loss for the year was HKD 140,706,000, compared to a profit of HKD 705,568,000 in 2022, indicating a substantial downturn in financial performance[115]. - The total comprehensive loss for the year was HKD 174,253,000, compared to a comprehensive income of HKD 654,250,000 in 2022[117]. - The company reported a basic and diluted loss per share of HKD 9.9 for the year, down from earnings of HKD 26.8 per share in the previous year[117]. - The company reported external customer revenue of HKD 211,985,000 for the year ending December 31, 2023, with contributions from various segments including medical and healthcare services (HKD 192,910,000) and pharmaceutical products (HKD 881,000)[138]. - The total loss before tax for the year was HKD 142,025,000, with a net loss of HKD 140,706,000 after tax[138]. - The group reported a loss of HKD 95,447,000 for the year 2023, compared to a profit of HKD 258,087,000 in 2022[197]. Revenue and Demand Trends - The company experienced a significant decrease in revenue from medical laboratory testing and health check services, which contributed to the overall lower demand in fiscal year 2023[22]. - The demand for COVID-19 related laboratory testing services significantly decreased due to the relaxation and subsequent cancellation of quarantine regulations[186]. - The revenue of the division decreased from approximately HKD 1,619,568,000 in 2022 to approximately HKD 192,910,000 in 2023, representing a decline of 88.09%[186]. - The total revenue for Hong Kong in 2023 was HKD 211,972,000, down from HKD 1,851,331,000 in 2022, indicating a significant decrease[191]. Assets and Liabilities - The company reported total assets of HKD 662,362,000 for the year ended December 31, 2023, down from HKD 1,470,491,000 in 2022[104]. - The total liabilities decreased from HKD 643,971,000 in 2022 to HKD 171,636,000 in 2023, a reduction of approximately 73%[105]. - The company’s total current assets decreased to HKD 261,166,000 in 2023 from HKD 884,757,000 in 2022[104]. - The company’s non-current assets included property, plant, and equipment valued at HKD 100,535,000, an increase from HKD 96,073,000 in 2022[104]. - The company’s goodwill decreased to HKD 107,181,000 in 2023 from HKD 110,083,000 in 2022[104]. - The company’s trade receivables and other receivables decreased significantly to HKD 39,636,000 in 2023 from HKD 765,547,000 in 2022[104]. Operational Changes and Strategies - The company plans to expand its routine medical laboratory testing and health check services to provide high-throughput public health screening services in Hong Kong, responding to the reduced demand for COVID-19 testing[39]. - The company has established a high-standard molecular biology laboratory in Hong Kong, providing next-generation sequencing (NGS) cancer companion diagnostic tests since July 2022, and is seeking collaborations with local hospitals and clinical laboratories[40]. - The company aims to become the first service provider in Greater China to offer boron neutron capture therapy for difficult-to-treat head and neck cancer patients, with plans to enhance advanced tumor radiation therapy services in mainland China, Hong Kong, and Macau[41]. - The company continues to evaluate its strategic options for future growth and market expansion[145]. Investments and Commitments - The company has committed to building and operating a cancer treatment center using a boron neutron capture therapy system in Hainan, with the system being supplied by Sumitomo Heavy Industries, Ltd.[53]. - The company injected a total of RMB 48,000,000 into Shanghai Longyao Biotechnology Co., Ltd. as part of its investment strategy[49]. - The company has authorized but not contracted capital commitments totaling HKD 208,295,000 for the fiscal year 2023, compared to HKD 237,541,000 in 2022[75]. - The company has made an initial payment of approximately HKD 51,765,000 for the purchase of boron neutron capture therapy equipment, with a total contract price of approximately HKD 176,820,000[77]. Employee and Operational Costs - The total employee cost for the fiscal year 2023 was approximately HK$92,607,000, a decrease from HK$166,735,000 in the previous year, with a total of 162 full-time employees as of December 31, 2023[60]. - The company’s operating expenses and financing costs were impacted by the overall decline in business activity due to the pandemic[30]. - The total contributions made by the company to the retirement plans for the fiscal year 2023 amounted to approximately HKD 2,996,000, a decrease from HKD 3,271,000 in the fiscal year 2022[61]. Governance and Compliance - The company has complied with the corporate governance code as per GEM listing rules, ensuring high standards of corporate governance and transparency[64]. - The company has maintained the public float as required by GEM listing rules[73]. - The company has conducted five audit committee meetings during the fiscal year 2023 to review financial performance and compliance procedures[71]. Future Outlook - Future outlook remains uncertain due to the substantial decrease in both total equity and non-controlling interests, which may impact investor confidence[106]. - The company is exploring market expansion opportunities, although specific strategies were not disclosed in the financial report[108].

智通财经APP讯，中国生物科技服务(08037)发布公告，海南省药品监督管理局已经于2024年1月28日批准进口(i)硼中子俘获治疗中子照射系统(型号： BNCTS-2-3);及(ii)硼中子俘获治疗之治疗规划程序(型号：BNCTDE-1)，作为在中华人民共和国海南自由贸易港博鰲乐城国际医疗旅游先行区硼中子俘获治疗癌症治疗中心使用之急需医疗装置。 该等医疗装置乃由Sumitomo Heavy Industries, Ltd.生产及供应，其将会在硼中子俘获治疗中心用作治疗不可切除的局部晚期或局部复发性头颈癌。 硼中子俘获治疗中子照射系统为一种紧凑型硼中子俘获治疗系统，可安装于医院内。其由质子加速器、质子束传输系统、中子照射装置及其他相关装置组成。传输系统会将来自加速器的质子束辐合或偏转以撞击放置于中子照射装置上的靶点。靶点由铍制成，而质子与铍原子核之间的碰撞会引发核反应，产生具有非常高能量的中子。硼中子俘获治疗中子照射系统中的相关装置会缓和并降低中子能量，安全地产生适合患者进行硼中子俘获治疗的稳定中子束。 硼中子俘获治疗之治疗规划程序根据轮廓资料(身体轮廓、器官形状、骨骼区域、治疗区域的形状╱组成部分及生物参数 ...

Financial Performance - For the three months ended September 30, 2023, the total revenue was HKD 18,355,000, a decrease of 96.9% compared to HKD 588,842,000 for the same period in 2022[12] - For the nine months ended September 30, 2023, the total revenue was HKD 200,712,000, down 84.3% from HKD 1,275,751,000 in the same period of 2022[12] - The company reported a net loss of HKD 54,976,000 for the three months ended September 30, 2023, compared to a profit of HKD 257,246,000 in the same period of 2022[24] - The division's revenue decreased from approximately HKD 1,044,983,000 in Q3 2022 to about HKD 185,559,000 in Q3 2023, representing a decline of 82.24%[43] - The group recorded a revenue of approximately HKD 200,712,000 in Q3 2023, a significant decrease of about 84.27% compared to HKD 1,275,751,000 in the same period of 2022[60] - The company reported a loss attributable to owners of the company of HKD 35,492,000 for the three months ended September 30, 2023, compared to a profit of HKD 91,296,000 in the same period of 2022[46] - The basic and diluted loss per share for the nine months ended September 30, 2023, was HKD (0.068), compared to a profit of HKD 0.166 for the same period in 2022[46] - The total comprehensive loss for the three months ended September 30, 2023, was HKD 57,374,000, compared to a total comprehensive income of HKD 239,090,000 in Q3 2022[70] Revenue Sources and Trends - The demand for COVID-19 related laboratory testing services significantly decreased due to the relaxation of quarantine regulations by the government, impacting revenue negatively[43] - The core business revenue from nucleic acid testing services and rapid antigen test kits has significantly decreased due to the easing threat of the COVID-19 pandemic[129] - The company continues to provide a variety of medical laboratory testing services and quality health check diagnostic services through three medical laboratories and three health check centers in Hong Kong[56] - The sales and distribution of healthcare-related and pharmaceutical products saw a significant decline, with revenue dropping from approximately HKD 216,557,000 in Q3 2022 to about HKD 473,000 in Q3 2023, a decrease of approximately 99.78%[63] - The revenue from logistics services decreased from approximately HKD 7,816,000 in Q3 2022 to about HKD 19,000 in Q3 2023, a decline of 99.76% due to intense market competition and reduced demand for testing supplies and sample logistics services[109] Expenses and Losses - The gross loss for the three months ended September 30, 2023, was HKD 11,403,000, compared to a gross profit of HKD 385,091,000 in Q3 2022[74] - The operating loss for the three months ended September 30, 2023, was HKD 49,241,000, compared to an operating profit of HKD 314,260,000 in the same period of 2022[74] - Administrative expenses for Q3 2023 were approximately HKD 108,728,000, a decrease of about HKD 48,827,000 or 30.99% compared to HKD 157,555,000 in Q3 2022, mainly due to reduced employee costs[103] - The company’s financing costs increased to approximately HKD 3,936,000 in Q3 2023, up from HKD 3,259,000 in Q3 2022, due to costs associated with convertible bonds issued[103] Government Support and Taxation - The company recognized government subsidies related to COVID-19 amounting to approximately HKD 1,661,000 during the nine months ended September 30, 2022[13] - The effective corporate income tax rate for the nine months ended September 30, 2023, was 25%, consistent with the same period in 2022[16] - The tax expense for the three months ending September 30, 2023, included a current tax expense of HKD (133,000) for Hong Kong profits tax[32] - The deferred tax for the period was recorded as HKD (302,000) for the three months ending September 30, 2023[32] - The group recognized government subsidies of approximately HKD 48,000 during the nine months ended September 30, 2023, related to employment support provided by the Chinese government[81] Corporate Governance and Shareholder Information - The company has not adopted new Hong Kong Financial Reporting Standards that have been issued but are not yet effective[11] - The company has issued shares listed on the GEM since June 17, 2004[9] - The company’s issued share capital as of September 30, 2023, was 963,231,150 shares with a par value of HKD 0.10 per share[142] - The company has a stock incentive plan that limits the total number of shares granted to no more than 10% of the total issued shares as of August 18, 2021[166] - The maximum rights for each participant in the stock incentive plan cannot exceed 1% of the total issued shares as of August 18, 2021[167] - The company confirmed that all directors complied with the prescribed trading standards and the code of conduct for securities trading during the third quarter of 2023[192] - The company has maintained the public float as specified under the GEM listing rules as of the report date[197] - The company has implemented corporate governance measures emphasizing integrity towards shareholders and the quality of information disclosure[193] Future Plans and Developments - The company aims to expand its market presence through exclusive distribution agreements for NMN products in Hong Kong and Macau[63] - The group plans to introduce new tests, including HPV DNA tests and colorectal cancer DNA tests, and seeks collaboration with the Hong Kong government and medical experts to enter the early screening market for colorectal cancer[116] - The company aims to become the first provider of boron neutron capture therapy for cancer treatment in the Greater China region, targeting advanced radiation therapy for late-stage cancer patients[117] - The company is progressing with the construction of a boron neutron capture therapy center in Boao, aiming for completion by the end of 2024 or early 2025[136] - The company has established partnerships with several domestic hospitals for cancer treatment services, including the upcoming Hainan boron neutron capture therapy center[136] Shareholder and Stock Options - The total number of stock options granted to directors and executives amounts to 8,220,000 shares, with a total exercise value of HKD 8,220,000[154] - The stock options granted to Ms. Xu Haiyin on January 6, 2023, total 5,000,000 shares, with an exercise price of HKD 1.45 per share[164] - During the third quarter of 2023, the company purchased a total of 5,295,000 shares at an approximate total cost of HKD 4,185,000[185] - A total of 582,000 incentive shares were granted to selected participants under the share incentive plan during the third quarter of 2023[185] - The number of incentive shares that can still be granted under the share incentive plan is 95,741,115, which represents 9.94% of the total issued shares of the company[186] - The share incentive plan has a validity period of 10 years from the date of adoption, expiring on August 17, 2031[200]